R&G PharmaStudies Co Ltd

R&G PharmaStudies (002931) trades near its 52‑week low as China’s biotech sector surges on AI‑driven drug discovery, offering investors a premium‑valued pharma stock poised to ride the innovation‑drug rally.

The Chinese stock market saw a significant rally in the medical sector, with R&G PharmaStudies Co Ltd and other companies experiencing notable gains, driven by strategic collaborations and strong financial performance.